Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glaucoma: Overview01:25

Glaucoma: Overview

1.6K
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.6K
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

1.5K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.5K
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

1.1K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

3.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.2K
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

2.9K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
2.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Factors Associated With Disability Improvement and Worsening Independent of Attacks in Patients With AQP4-IgG+ NMOSD and MOGAD: A Multicenter Cohort Study.

Neurology·2026
Same author

Sex-specific analysis of early disease course and treatment in a German multiple sclerosis cohort.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Autologous haematopoietic stem cell transplantation in multiple sclerosis: outcomes and predictors from German real-world data.

Journal of neurology, neurosurgery, and psychiatry·2026
Same author

Socioeconomic impact of depression and pain in patients with neuromyelitis optica spectrum disorders.

Neurological research and practice·2026
Same author

Impaired suppressive effect of FoxP3 regulatory T cells on B cells in multiple sclerosis.

Journal of neuroinflammation·2026
Same author

HLA Associations Differ by Ethnicity and Aquaporin-4 Antibody Status in Patients With Neuromyelitis Optica Spectrum Disorders.

Neurology(R) neuroimmunology & neuroinflammation·2026

Related Experiment Video

Updated: Mar 7, 2026

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
09:29

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4

Published on: August 21, 2017

12.1K

[Neuromyelitis optica].

Florence Pache1, Brigitte Wildemann2, Friedemann Paul1

  • 1NeuroCure Clinical Research Center und Klinisches und Experimentelles Forschungszentrum für Multiple Sklerose, Klinik für Neurologie, Charité - Universitätsmedizin Berlin, Berlin, Deutschland.

Fortschritte Der Neurologie-Psychiatrie
|February 25, 2017
PubMed
Summary
This summary is machine-generated.

Neuromyelitis optica (NMO) is an autoimmune CNS disorder affecting optic nerves and spinal cord. Aquaporin-4 IgG antibodies aid diagnosis, distinguishing NMO from MS and guiding treatment strategies.

More Related Videos

Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients
12:23

Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients

Published on: April 14, 2014

14.6K
Visual Evoked Potential Recording in a Rat Model of Experimental Optic Nerve Demyelination
06:49

Visual Evoked Potential Recording in a Rat Model of Experimental Optic Nerve Demyelination

Published on: July 29, 2015

12.9K

Related Experiment Videos

Last Updated: Mar 7, 2026

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
09:29

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4

Published on: August 21, 2017

12.1K
Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients
12:23

Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients

Published on: April 14, 2014

14.6K
Visual Evoked Potential Recording in a Rat Model of Experimental Optic Nerve Demyelination
06:49

Visual Evoked Potential Recording in a Rat Model of Experimental Optic Nerve Demyelination

Published on: July 29, 2015

12.9K

Area of Science:

  • Neuroimmunology
  • Autoimmune Disorders
  • Central Nervous System Diseases

Background:

  • Neuromyelitis optica (NMO) is a rare autoimmune disease targeting the central nervous system (CNS).
  • NMO primarily affects the spinal cord and optic nerves, characterized by specific neuropathological findings.
  • Aquaporin-4 IgG (AQP4-IgG) autoantibodies are key biomarkers, present in ~80% of NMO patients.

Purpose of the Study:

  • To summarize the key features of Neuromyelitis Optica (NMO) and NMO spectrum disorders.
  • To highlight the diagnostic significance of AQP4-IgG autoantibodies.
  • To outline current treatment approaches for NMO exacerbations and long-term management.

Main Methods:

  • Review of neuropathological hallmarks of NMO.
  • Analysis of diagnostic criteria and biomarkers, including AQP4-IgG.
  • Summary of clinical manifestations and treatment strategies for NMO.

Main Results:

  • NMO neuropathology involves antibody/complement deposits, astrocyte loss, and inflammatory infiltrates.
  • AQP4-IgG autoantibodies are pathognomonic and help differentiate NMO from multiple sclerosis.
  • NMO spectrum disorders include brainstem and diencephalon involvement, with area postrema lesions causing severe symptoms.

Conclusions:

  • NMO is an AQP4-IgG-mediated autoimmune disorder of the CNS.
  • Early diagnosis is facilitated by updated consensus criteria and AQP4-IgG testing.
  • Treatment involves acute management with steroids/PLEX and long-term immunosuppression or B-cell depletion.